China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
AFT Leaves X Over AI-Generated Images of Minors 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
BETHESDA, Md., April 04, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that on April 3, 2017, it received a NYSE MKT LLC notice indicating that the Company has fallen below certain NYSE MKT continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on March 31, 2016, as set forth in Section 704 of the Company Guide.
To regain compliance, the Company will hold the annual meeting promptly after filing its Form 10-K for fiscal year ended March 31, 2017, which is due by June 30, 2017, following the submission of a plan in form prescribed by the NYSE MKT LLC by April 10, 2017.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life-altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
